Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTA-01
- Development stage
- Preclinical
- Lead developer
- CTCELLS
- Modality
- Antibody-Based Therapeutics
01
Overview
CTA-01 is an antibody drug developed by CTCELLS, Inc. It functions as an antagonist of the Epidermal Growth Factor Receptor (EGFR) and is currently in preclinical development. Its therapeutic potential is being explored for various neoplasms, digestive system disorders, and respiratory diseases, with active indications including colorectal cancer and non-small cell lung cancer.
02
Targets
Beyond the preview
Go deeper on CTA-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTA-01.